Related Experiment Videos
[Torecan-induced neuroleptic malignant syndrome]
S Bulvik1, Z Shimoni, C L Kaplan
1Dept. of Medicine B, Central Hospital of the Emek, Afula.
Harefuah
|May 15, 1990
Summary
Neuroleptic malignant syndrome (NMS) is a rare but severe reaction to neuroleptic medications. Early recognition and prompt treatment are crucial for managing this life-threatening condition.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Neuroleptic malignant syndrome (NMS) is a rare, severe, and potentially fatal complication associated with neuroleptic drug treatment.
- It is characterized by hyperthermia, extrapyramidal signs, autonomic instability, and altered consciousness.
- The underlying pathophysiology is thought to involve dopamine receptor blockade in the central nervous system.
Observation:
- A case study of a 52-year-old diabetic woman who developed NMS is presented.
- The patient experienced NMS after a 3-month course of Torecan (thiethylperazine), a phenothiazine derivative, prescribed for dizziness.
Findings:
- The patient's presentation included the hallmark symptoms of NMS, indicating a severe adverse drug reaction.
- This case highlights the risk of NMS even with prolonged use of certain neuroleptic agents.
Implications:
- Early diagnosis and immediate intervention are critical for improving patient outcomes in NMS.
- Increased awareness among clinicians regarding NMS presentation and risk factors is essential for prompt management.